MINI FUTURE LONG - ZEALAND PHARMA | Delayed Börse Stuttgart 12:05:09 2024-06-19 pm EDT | ||
| 6.24 EUR | +3.31% |
|
| Current month | +1.17% | ||
| 1 month | +10.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 6.24 | +3.31% |
| 24-06-18 | 6.04 | -0.33% |
| 24-06-17 | 6.06 | -4.11% |
| 24-06-14 | 6.32 | +3.27% |
| 24-06-13 | 6.12 | +6.99% |
Delayed Quote Börse Stuttgart
Last update June 19, 2024 at 12:05 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1S9D |
| ISIN | DE000MB1S9D1 |
| Date issued | 2022-12-27 |
| Strike | 189.5 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.69 € |
|---|---|
| Lowest since issue | 0.33 € |
| Spread | 0.1 € |
| Spread % | 1.58% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
640
DKK
Average target price
790.9
DKK
Spread / Average Target
+23.57%
- Stock Market
- Certificates
- Certificat
